Document is current
Any future updates will be listed below
-
Authors
Kesselheim, Aaron S.
Gagne, Joshua J.
-
Funding
Funding for this research was provided by:
U.S. Food and Drug Administration
- License Information
-
More Information
Article History
First Online: 24 June 2015
Compliance with ethical standards
:
: Preparation of this manuscript was supported by a grant from the FDA Office of Generic Drugs to the Brigham and Women’s Hospital.
: Aaron Kesselheim receives research funding from the Greenwall Faculty Scholar in Bioethics, and the Harvard Program in Therapeutic Science. Joshua Gagne is the Principal Investigator on research funding to the Brigham and Women’s Hospital from the Harvard Catalyst, the FDA Mini-Sentinel program, the Patient-Centered Outcomes Research Institute, the Agency for Healthcare Research and Quality, and Novartis Pharmaceuticals Corporation. Members of the FDA Office of Generic Drugs provided comments on an early draft of this manuscript, but had no role in its preparation or approval.
Free to read: This content has been made available to all.
